Shopping Cart
Remove All
Your shopping cart is currently empty
Fanapanel
😃Good
Catalog No. T13405LCas No. 161605-73-8
Alias ZK200775, ZK 200775, MPQX
Fanapanel (ZK200775) is a quinoxalinedione derivative and potent competitive antagonist of AMPAR for cerebrovascular-related studies.
Fanapanel
😃Good
Catalog No. T13405LAlias ZK200775, ZK 200775, MPQXCas No. 161605-73-8
Fanapanel (ZK200775) is a quinoxalinedione derivative and potent competitive antagonist of AMPAR for cerebrovascular-related studies.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $69 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Batch Information
Select Batch
Appearance:Solid
Color:White
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Fanapanel (ZK200775) is a quinoxalinedione derivative and potent competitive antagonist of AMPAR for cerebrovascular-related studies. |
| Targets&IC50 | AMPA/kainate receptor:21 nM |
| In vitro | In rat cortical slice experiments, the inhibitory effect of Fanapanel on AMPA receptors was measured to assess its activity. The Results showed that the IC50 value for Fanapanel's inhibition of AMPA-induced currents was 21 nM, demonstrating strong neuroprotective and anticonvulsant effects [1]. |
| In vivo | In the permanent MCAO model, intravenous infusion of Fanapanel (0.1-10 mg/kg/h for 6 hours) reduced the infarct volume by 24-34%, and it remained effective even when administered 1-5 hours later (reducing infarct volume by 20-30%). In the transient MCAO model, immediate or delayed injection of Fanapanel (0.01-3 mg/kg/h) 2 hours after reperfusion reduced the infarct volume by approximately 45%. In the gerbil global cerebral ischemia model, Fanapanel protected the hippocampal CA1 region. Long-term toxicity studies (rats 6 mg/kg/h, dogs 0.2 mg/kg/h for 4 weeks) did not show renal or neurotoxicity [1]. |
| Synonyms | ZK200775, ZK 200775, MPQX |
| Molecular Weight | 409.25 |
| Formula | C14H15F3N3O6P |
| Cas No. | 161605-73-8 |
| Smiles | O=C1NC=2C=C(C(=CC2N(C1=O)CP(=O)(O)O)N3CCOCC3)C(F)(F)F |
| Relative Density. | 1.615g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: 1 mg/mL (2.44 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Fanapanel | purchase Fanapanel | Fanapanel cost | order Fanapanel | Fanapanel chemical structure | Fanapanel in vivo | Fanapanel in vitro | Fanapanel formula | Fanapanel molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.